메뉴 건너뛰기
European Journal of Clinical Pharmacology
Volumn 55, Issue 6, 1999, Pages 457-459
Dextromethorphan O-demethylation polymorphism in an African-American population
Author keywords

African Americans; CYP2D6; Genetic polymorphism
Indexed keywords

DEXTROMETHORPHAN;
EID: 0032812631     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050656     Document Type: Article
Times cited : (17)
References (12)
  • 1
    • 0026004805 scopus 로고
    • Lower prevalence of the debrisoquin oxidation poor metabolizer phenotype in American black versus white subjects
    • Relling MV, Cherrie J, Schell MJ, et al (1991) Lower prevalence of the debrisoquin oxidation poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 50: 308-313
    • (1991) Clin Pharmacol Ther , vol.50 , pp. 308-313
    • Relling, M.V.1    Cherrie, J.2    Schell, M.J.3
  • 2
    • 0028934224 scopus 로고
    • Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy Black American adult subjects
    • Marinac JS, Foxworth JW, Willsie SK (1995) Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy Black American adult subjects. Ther Drug Monit 17: 120-124
    • (1995) Ther Drug Monit , vol.17 , pp. 120-124
    • Marinac, J.S.1    Foxworth, J.W.2    Willsie, S.K.3
  • 3
    • 0021336171 scopus 로고
    • Quantitative determination of dextromethorphan and three metabolites in urine by reversed-phase high-performance liquid chromatography
    • Park YH, Kullberg MP, Hinswardk ON (1984) Quantitative determination of dextromethorphan and three metabolites in urine by reversed-phase high-performance liquid chromatography. J Pharm Sci 73: 24-29
    • (1984) J Pharm Sci , vol.73 , pp. 24-29
    • Park, Y.H.1    Kullberg, M.P.2    Hinswardk, O.N.3
  • 4
    • 0018564985 scopus 로고
    • Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians
    • Woolhouse NM, Andoh B, Mahgoub A, et al (1979) Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther 26: 584-591
    • (1979) Clin Pharmacol Ther , vol.26 , pp. 584-591
    • Woolhouse, N.M.1    Andoh, B.2    Mahgoub, A.3
  • 5
    • 0021846817 scopus 로고
    • Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians
    • Woolhouse NM, Eichelbaum M, Oates NS, et al (1985) Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 37: 512-527
    • (1985) Clin Pharmacol Ther , vol.37 , pp. 512-527
    • Woolhouse, N.M.1    Eichelbaum, M.2    Oates, N.S.3
  • 6
    • 0023196288 scopus 로고
    • Chromosome assignment of human cytochrome P-450 (debrisoquin/sparteine type) to chromosome 22
    • Eichelbaum M, Baur MP, Dengler HJ, et al (1987) Chromosome assignment of human cytochrome P-450 (debrisoquin/sparteine type) to chromosome 22. Br J Clin Pharmacol 23: 455-458
    • (1987) Br J Clin Pharmacol , vol.23 , pp. 455-458
    • Eichelbaum, M.1    Baur, M.P.2    Dengler, H.J.3
  • 7
    • 0019140947 scopus 로고
    • A study of the debrisoquin hydroxylation polymorphism in a Nigerian population
    • Mbanefo C, Bababunmi EA, Mahgoub A, et al (1980) A study of the debrisoquin hydroxylation polymorphism in a Nigerian population. Xenobiotica 10: 811-818
    • (1980) Xenobiotica , vol.10 , pp. 811-818
    • Mbanefo, C.1    Bababunmi, E.A.2    Mahgoub, A.3
  • 8
    • 0020409410 scopus 로고
    • Oxidation phenotype: A major determinant of metoprolol metabolism and response
    • Lennard MS, Silas JH, Freestone S, et al (1982) Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558-1560
    • (1982) N Engl J Med , vol.307 , pp. 1558-1560
    • Lennard, M.S.1    Silas, J.H.2    Freestone, S.3
  • 9
    • 0022496369 scopus 로고
    • Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation
    • Lyun AO, Lennari MS, Tucker GT, Woods HF (1986) Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 40: 387-399
    • (1986) Clin Pharmacol Ther , vol.40 , pp. 387-399
    • Lyun, A.O.1    Lennari, M.S.2    Tucker, G.T.3    Woods, H.F.4
  • 10
    • 0027755278 scopus 로고
    • Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents
    • Llerena A, Herraiz AG, Cobaleda J, et al (1993) Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 54: 606-611
    • (1993) Clin Pharmacol Ther , vol.54 , pp. 606-611
    • Llerena, A.1    Herraiz, A.G.2    Cobaleda, J.3
  • 11
    • 84973847615 scopus 로고
    • Polymorphism of the 4-hydroxylation of debrisoquin in the San Bushmen of Southern Africa
    • Sommers DK, Monerieff J, Avenant J (1988) Polymorphism of the 4-hydroxylation of debrisoquin in the San Bushmen of Southern Africa. Hum Toxicol 7: 273-276
    • (1988) Hum Toxicol , vol.7 , pp. 273-276
    • Sommers, D.K.1    Monerieff, J.2    Avenant, J.3
  • 12
    • 0027248189 scopus 로고
    • Debrisoquin and metoprolol oxidation in Zambians: A population study
    • Simooya O, Njunju E, Hodjegan AR, et al (1993) Debrisoquin and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 3: 205-208
    • (1993) Pharmacogenetics , vol.3 , pp. 205-208
    • Simooya, O.1    Njunju, E.2    Hodjegan, A.R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.